De novo nontuberculous mycobacterial disease following lung transplantation: a systematic review of clinical characteristics and outcomes

De novo nontuberculous mycobacterial (NTM) disease after lung transplantation remains poorly characterized. We systematically reviewed its clinical features, microbiologic spectrum, treatment, and outcomes. PubMed, Embase, and Scopus were searched from inception through October 15, 2025, following PRISMA 2020 guidelines. Studies reporting de novo NTM disease after lung transplantation, distinct from pre-transplant colonization and donor-derived infection, were included. We extracted patient characteristics, NTM species, treatment, microbiologic clearance, graft outcomes, and mortality. Methodological quality was assessed using Joanna Briggs Institute critical appraisal checklists for case reports and case series and the Newcastle–Ottawa Scale for retrospective cohorts. Findings were synthesized descriptively because of clinical and methodological heterogeneity. Thirteen studies comprising 60 patients were included. Bilateral lung transplantation was performed in 41/60 patients (68.3%). Among 39 patients with available demographic data, the median age was 53 years (interquartile range [IQR], 38.5–65), and 23/39 (59.0%) were male. Sixty-one NTM organisms were reported, including one dual isolation. Mycobacterium abscessus complex/M. chelonae–abscessus group (30/61, 49.2%) and Mycobacterium avium complex (23/61, 37.7%) predominated. Median time to disease onset was 12 months (IQR, 4–24). All patients had respiratory involvement; 56/60 (93.3%) had no documented dissemination, whereas 4/60 (6.7%) had disseminated disease. Among 14 patients with reported microbiological clearance and usable duration data, median reported treatment exposure was 9.1 months (IQR, 4.8–12.0), including therapy truncated by death. Source-defined microbiologic clearance occurred in 17/25 patients (68.0%) with a reported binary outcome. Twelve-month mortality was 20/60 (33.3%), and adverse graft outcomes occurred in 13/33 patients (39.4%) with reported graft outcomes. Most studies had moderate risk of bias. Mortality and adverse graft outcomes were frequently reported among published cases of de novo NTM disease after lung transplantation. The predominance of small case reports and series, heterogeneous diagnostic and surveillance practices, and incomplete outcome reporting limit generalizability and conclusions about treatment. Prospective multicenter studies using standardized definitions and outcomes are needed. PROSPERO CRD420251170157.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-11-18
DOI
https://doi.org/10.1186/s12879-026-14760-y
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

De novo nontuberculous mycobacterial disease following lung transplantation: a systematic review of clinical characteristics and outcomes

Siri Peddineni, Megha Priyadarshi, Akankcha Alok, Manish Soneja et al.
BMC Infectious Diseases
Mycobacterium research and diagnosis
article

De novo nontuberculous mycobacterial disease following lung transplantation: a systematic review of clinical characteristics and outcomes

Siri Peddineni, Megha Priyadarshi, Akankcha Alok, Manish Soneja, Gautam Kalyatanda, Sunit Sikdar
article en

Abstract

De novo nontuberculous mycobacterial (NTM) disease after lung transplantation remains poorly characterized. We systematically reviewed its clinical features, microbiologic spectrum, treatment, and outcomes. PubMed, Embase, and Scopus were searched from inception through October 15, 2025, following PRISMA 2020 guidelines. Studies reporting de novo NTM disease after lung transplantation, distinct from pre-transplant colonization and donor-derived infection, were included. We extracted patient characteristics, NTM species, treatment, microbiologic clearance, graft outcomes, and mortality. Methodological quality was assessed using Joanna Briggs Institute critical appraisal checklists for case reports and case series and the Newcastle–Ottawa Scale for retrospective cohorts. Findings were synthesized descriptively because of clinical and methodological heterogeneity. Thirteen studies comprising 60 patients were included. Bilateral lung transplantation was performed in 41/60 patients (68.3%). Among 39 patients with available demographic data, the median age was 53 years (interquartile range [IQR], 38.5–65), and 23/39 (59.0%) were male. Sixty-one NTM organisms were reported, including one dual isolation. Mycobacterium abscessus complex/M. chelonae–abscessus group (30/61, 49.2%) and Mycobacterium avium complex (23/61, 37.7%) predominated. Median time to disease onset was 12 months (IQR, 4–24). All patients had respiratory involvement; 56/60 (93.3%) had no documented dissemination, whereas 4/60 (6.7%) had disseminated disease. Among 14 patients with reported microbiological clearance and usable duration data, median reported treatment exposure was 9.1 months (IQR, 4.8–12.0), including therapy truncated by death. Source-defined microbiologic clearance occurred in 17/25 patients (68.0%) with a reported binary outcome. Twelve-month mortality was 20/60 (33.3%), and adverse graft outcomes occurred in 13/33 patients (39.4%) with reported graft outcomes. Most studies had moderate risk of bias. Mortality and adverse graft outcomes were frequently reported among published cases of de novo NTM disease after lung transplantation. The predominance of small case reports and series, heterogeneous diagnostic and surveillance practices, and incomplete outcome reporting limit generalizability and conclusions about treatment. Prospective multicenter studies using standardized definitions and outcomes are needed. PROSPERO CRD420251170157.

BMC Infectious Diseases
University of Florida Health (US), University of Florida (US), All India Institute of Medical Sciences (IN)
Good health and well-being
Mycobacterium research and diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon